PeerView Oncology

 

PeerView Oncology
E

Challenging Case of a 63 y/o Never-Smoking Female With TTF-1+ Lung Adenocarcinoma: Should We Initiate IO + Chemo? How Should We Adapt the Treatment if the Tumor Is EGFR+?

By PeerView Oncology FEATURING Edward Garon, John Heymach
By PeerView Oncology FEATURING Edward Garon, John Heymach
240 views
November 11, 2020
1 Comment
Login to view comments. Click here to Login

Featured Video

13:04
Winship Cancer Institute - Emory University

Treatment-Related Quality of Life in MF

Feat. A. Hunter

Featured Video

15:14
Icahn School of Medicine at Mount Sinai

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay
Lung
17:03
PeerView Oncology

Challenging Case of a 63 y/o Never-Smoking Female With TTF-1+ Lung A…

Feat. E. Garon, J. Heymach
15:20
PeerView Oncology

Locally Advanced and Early NSCLC IO Update: Will IO Change the Multi…

Feat. B. Stiles
15:18
PeerView Oncology

Managing EGFR+ NSCLC With CNS Metastases: Is There a Difference in C…

Feat. S. Patel
02:22
PeerView Oncology

45 y/o With EGFR+ NSCLC and Brain Mets: Should We Consider Mono or C…

Feat. S. Patel, M. Ahluwalia, K. Beal
05:24
PeerView Oncology

64 y/o Female With Newly Diagnosed Stage 4 NSCLC, EGFR exon 19 Mutat…

Feat. S. Patel, M. Ahluwalia, K. Beal
17:21
PeerView Oncology

Management of EGFR-Mutant Lung Cancer With Central Nervous System Me…

Feat. S. Patel, M. Ahluwalia, K. Beal
04:37
PeerView Oncology

41 y/o Female With Newly Diagnosed EGFR+ Stage 4 NSCLC and Brain Me…

Feat. S. Patel, M. Ahluwalia, K. Beal